A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

It doesn’t stop people from getting worse ... that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including ...

Biogen’s treatment for Alzheimer’s was ... would ‘realign resources’ for its Alzheimer’s portfolio and stop selling Aduhelm. The highly anticipated launch, along with blockbuster ...

Lilly maintains that the potential to stop ... of Aduhelm’s rollout - marred by controversy over its efficacy data - Leqembi started slowly, but has shown signs of picking up. Biogen said ...

Earlier this year, Biogen decided to discontinue the drug that it had named Aduhelm, which the company said was ‘not related to any safety or efficacy concerns.’ They've cured countless ...

These treatments are intended to slow neurodegeneration and disease progression. In January 2024, Biogen, the maker of Aduhelm, announced that it would discontinue sales and clinical trials for the ...

In June 2021, the Food and Drug Administration (FDA) approved Aduhelm for treating Alzheimer's disease ... no benefit in slowing cognitive decline. In January 2024, Biogen announced it would ...

In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...